Core A: Administration The Administrative Core A (Admin Core) provides the administrative framework to support the four Projects and the other Core of this PPG. Its main focus is to allow the PPG investigators to dedicate their efforts on scientific advances to fulfill the goals of this PPG. The Core is led by Antoni Ribas, M.D. with the Core Co- lnvestigator David Gjertson, Ph.D., the senior PPG biostatistician. With this resubmission Core A incorporates a new service, bioinformatics support, which is a common need for the four Projects to allow adequate interpretation of high throughput data and the ability to use advanced algorithms for its analysis This will be provided by Stan Nelson, M.D. and Tom Graeber, Ph.D. It is supported by a staff biostatistician, a regulatory coordinator, an administrative and a fund manager, and a clinical trials coordinator and data manager. The Core has two specific Aims.
Aim 1 is focused on fostering the scientific aspects of the PPG providing oversight of meeting the milestones and objectives for each Project and Core. This will be facilitated by a series of in-process and formal evaluation meetings with the oversight of the Internal Advisory Board (lAB) made up by four senior Investigators at UCLA and Caltech, James Economou, M.D., Ph.D., James Heath, Ph.D. (Caltech), Owen Witte, M.D., and Hong Wu, Ph.D. This oversight and scientific support is extended by the engagement of three External Expert Consultants (EEC). Boris Bastian, M.D., Ph.D. (UCSF), Charles Sawyers, M.D. (MSKCC) and Cassian Yee (Fred Hutch).
Aim 2 is focused on providing the appropriate administrative and fiscal support for the daily activities within PPG. This includes administrative and coordination support, facilitating data and resource sharing plans, clinical trial and biospecimen regulatory, study coordination and data management.
The Admin Core will support all Projects and Cores to allow them to focus the efforts on the proposed scientific plans. As such, it is an integral part of the PPG scientific goals and provides Its relevance for the proposed patient-oriented research.
|Cheng, Larry C; Li, Zhen; Graeber, Thomas G et al. (2018) Phosphopeptide Enrichment Coupled with Label-free Quantitative Mass Spectrometry to Investigate the Phosphoproteome in Prostate Cancer. J Vis Exp :|
|Jan, Yu Jen; Chen, Jie-Fu; Zhu, Yazhen et al. (2018) NanoVelcro rare-cell assays for detection and characterization of circulating tumor cells. Adv Drug Deliv Rev 125:78-93|
|Ribas, Antoni; Wolchok, Jedd D (2018) Cancer immunotherapy using checkpoint blockade. Science 359:1350-1355|
|Park, Jung Wook; Lee, John K; Sheu, Katherine M et al. (2018) Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage. Science 362:91-95|
|Hong, Aayoung; Moriceau, Gatien; Sun, Lu et al. (2018) Exploiting Drug Addiction Mechanisms to Select against MAPKi-Resistant Melanoma. Cancer Discov 8:74-93|
|Nowicki, Theodore S; Hu-Lieskovan, Siwen; Ribas, Antoni (2018) Mechanisms of Resistance to PD-1 and PD-L1 Blockade. Cancer J 24:47-53|
|Puig-Saus, Cristina; Parisi, Giulia; Garcia-Diaz, Angel et al. (2018) IND-Enabling Studies for a Clinical Trial to Genetically Program a Persistent Cancer-Targeted Immune System. Clin Cancer Res :|
|Moschos, Stergios J; Sullivan, Ryan J; Hwu, Wen-Jen et al. (2018) Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors. JCI Insight 3:|
|Tsoi, Jennifer; Robert, Lidia; Paraiso, Kim et al. (2018) Multi-stage Differentiation Defines Melanoma Subtypes with Differential Vulnerability to Drug-Induced Iron-Dependent Oxidative Stress. Cancer Cell 33:890-904.e5|
|Grasso, Catherine S; Giannakis, Marios; Wells, Daniel K et al. (2018) Genetic Mechanisms of Immune Evasion in Colorectal Cancer. Cancer Discov 8:730-749|
Showing the most recent 10 out of 72 publications